{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108409","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.839720+00:00","generated_at":"2026-05-17T12:58:20.425747+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026","bullets":["Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.","Cash, equivalents, marketable securities $138.5M at June 30; pro forma $203.6M incl. $65.1M July offering; runway into Q4 2026.","FDA recommends safety database: 30+ participants on 50 mg for 6 months, subset of 10 for 1 year.","Initial 50 mg open-label and adolescent PK run-in data expected September 2025.","Global Phase 3 sites identified in US, EU, UK, Canada, Australia; patient recruitment to begin later 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108409","json":"https://secwatch.observer/filing/0000950170-25-108409.json","markdown":"https://secwatch.observer/filing/0000950170-25-108409.md","text":"https://secwatch.observer/filing/0000950170-25-108409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/0000950170-25-108409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/lrmr-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:58:20.425747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}